Skip to content
Colorado State University College of Veterinary Medicine and Biomedical Sciences College of Veterinary Medicine and Biomedical Sciences
Department of Clinical Sciences
  

 

 

David Vail
Professor
Oncology

 

Degrees
1) B.Sc. (Microbiology), University of Alberta
2) M.S. (Medical Oncology), Colorado State University,
3) D.V.M., University of Saskatchewan

Specialty Certification: Diplomate ACVIM (Oncology)

Clinical Interests: Medical Oncology

Research Interests: Experimental Cancer Therapeutics

Selected Publications:
Vail DM, Amanea MA, Colbern GT, Martin FJ, Hilger R-A, Working PK. Doxil: Proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol: In press, 2004.

Katayama R, Huelsmeyer MK, Marr AK, Kurzman ID, Thamm DH, Vail DM. Imatinib Mesylate Inhibits Platelet-Derived Growth Factor Activity And Increases Chemosensitivity In Feline Vaccine-Associated Sarcoma, Canc Chem Pharm 54:25-33,2004.

Poirier VJ, Huelsmeyer MK, Kurzman ID, Thamm DH, Vail DM. The bisphosphonates alendronate and zoledronate are inhibitors of canine and human osteosarcoma cell growth in vitro. J Veterinary Comp Oncol,1:207-215, 2003.

Khanna C, Vail DM. Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers. Current Cancer Drug Targets 3:265-73, 2003.

Vail DM, ID Kurzman, PA Glawe, MG O’Brien, R Chun, LD Garrett, JE O’Bradovich, R Fred, C Khanna, GT Colbern, PK Working. Stealth liposomal cisplatin versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma in the dog: A randomized multicenter clinical trial. Canc Chem Pharm 50:131-136, 2002.

Vail DM, MacEwen EG. Spontaneous Occurring Tumors of Companion Animals as Models for Human Cancer. Vail, DM;MacEwen, EG. , Cancer Invest 18: 781-792, 2000.

Hershey AE, Kurzman ID, Bohling C, Forrest LJ, Stonerook M, Placke ME, Imondi AR, Vail DM. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: Proof of principle in a companion animal model. Clin Canc Res, 5:2653-2659, 1999.

Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 4:1567-1571, 1998

Vail DM, Kravis LD, Cooley AJ, Chun R, MacEwen EG. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol 39:410-416, 1997.

Vail DM, Kisseberth WC, Obradovich JE, et al. Assessment of potential doubling time, argyrophilic nucleolar organizing regions, and proliferating cell nuclear antigen as predictors of therapy response in canine Non-Hodgkin’s lymphoma. Exper Hematol 24:807-815, 1996.

Vail DM, MacEwen EG, Kurzman ID, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) immunotherapy for splenic hemangiosarcoma in the dog: A randomized multi-institutional clinical trial. Clin Canc Res 1:1165-1170, 1995.

Graduate Students/ Residents: Current: Drs. Marrie Mullins, Claudia Walter, Kim Hillers, Kelvin Kow